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Randomised controlled trials (RCTs) have shown its superiority to pharmacological treatment in terms of symptom control, rhythm control and mortality in selected patients; observational studies have also suggested a decreased risk of stroke. 1, 2 Pulmonary vein isolation (PVI) is the standard endpoint, but studies have reported variable and improvable efficacy rates ranging from 20% to 80% depending on the study population. 3 In addition, a substantial proportion of patients require repeat procedures. Pre-existing and/or progression of extrapulmonary vein (PV) AF substrate likely plays a significant role in PVI non-responders and numerous substrate modification strategies have been investigated. However, given the large interindividual variability of electrical and anatomical AF substrate, achieving optimal patient outcomes requires individualised management. To this effect, the following key issues need to be addressed by clinicians and researchers:
how to identify optimal candidates likely to benefit from AF ablation and which procedure endpoint(s) should be aimed at. This non-systematic review summarises the current literature regarding clinical practice, the most commonly proposed solutions and recent developments.
Optimal Candidate Selection
Clinical Stratification
AF Type
There is overwhelming evidence that the clinical AF phenotype is associated with post-ablation outcome, with progressively higher rates of arrhythmia recurrence for paroxysmal, persistent and longstanding persistent AF patients, respectively. [3] [4] [5] Continuous duration of persistent AF and duration of AF history also correlate with postablation recurrence, and reports have suggested that ablation early in the course of the disease may prevent progression and even induce reverse atrial remodelling. [6] [7] [8] [9] As a result, substantial weight is generally accorded to AF type when evaluating the indication for AF ablation, as well as the ablation strategy itself. This is reflected in international recommendations. [3] [4] [5] However, current definitions of AF types are derived from historybased arbitrary duration cut-offs rather than from prognostic studies and they lack objective validation with measured AF burden. 10 Several large studies reported no association between AF type and recurrent AF after ablation when adjusting for other -likely stronger -predictors such as atrial fibrosis (see the imaging section). Therefore, while AF type is the most well established stratification tool for patient selection, it remains a relatively inaccurate predictor of ablation outcome as currently defined and other individual factors should also be considered.
AF Risk Factors
Numerous risk factors for arrhythmia recurrence after AF ablation have been reported and are summarised in Supplementary Material Table 1 .
recurrence after ablation. PV reconnection is traditionally considered to be a major cause of recurrence, but a recent meta-analysis found only a weak association, with 58% of AF-free patients also exhibiting PV reconnection. 3, 12 Based on current knowledge and ablation strategies, it may be reasonable to avoid ablation in patients estimated to have very low success probability based on substantial and unmodifiable risk factors.
However, as discussed for heart failure (HF) in the next section, it will be crucial to determine if some of these patients may benefit from ablation despite lower success rates. Furthermore, observational data have shown risk factor management (RFM) to decrease the risk of post-ablation AF recurrence to rates comparable to low-risk patients. 18 In the Aggressive Risk factor REduction STudy for Atrial Fibrillation and Implications for the Outcome of Ablation (ARREST-AF) observational cohort study, RFM including aggressive management of blood pressure, weight, lipids, glucose, sleep apnoea, smoking and alcohol consumption, was offered to AF patients undergoing CA.
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After an average 42-month follow-up, RFM was associated with a fivefold increase in arrhythmia-free survival compared with controls who underwent CA without structured RFM (87% versus 18%, respectively; p<0.001). While there are no prospective data investigating different ablation strategies in these populations, it should be noted that obstructive sleep apnoea has been associated with an increased prevalence of non-PV triggers.
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Heart Failure 24 However, the effect was relatively small: the average difference between patients with and without recurrence was 0.8 ml for LA volume and 0.6 ml/m 2 for LA volume index. Therefore, LA size alone does not appear to be a reliable prognostic indicator for clinical decision making.
Atrial tissue fibrosis is a prominent feature of atrial structural remodelling in AF patients and an established determinant of AF progression. 25 The Salt Lake City group quantified LA fibrosis by delayed-enhancement MRI and demonstrated an independent association with arrhythmia recurrence following AF ablation. [26] [27] [28] The authors proposed a staging system based on the extent of fibrosis with Utah stages I through IV corresponding to <10%, ≥10%-<20%, ≥20%-<30% and ≥30% of the LA wall volume, respectively. The cumulative incidence of recurrent arrhythmia at one year after ablation was 15%, 33%, 46% and 51%
for stages I-IV, respectively. 28 At five years, the cumulative incidence of recurrent arrhythmia was 53%, 66%, 72% and 87%, respectively. The on-going DECAAF II study will examine the efficacy of adjunctive fibrosis-guided ablation compared with PVI alone to prevent arrhythmia recurrence after AF ablation.
Imaging Atrial Mechanical Remodelling
The mechanical function of the LA consists of the reservoir, conduit and booster pump functions, the three of which are altered in AF and have been shown to predict AF recurrence after ablation. [30] [31] [32] In
Electrophysiology and Ablation a meta-analysis of eight prospective studies, LA strain by 2D speckletracking echocardiography (a measure of the booster pump function)
predicted AF recurrence at an average 11.3 months post-ablation with 78% sensitivity, 75% specificity, mean AUC 0.798 (95% CI [0.70-0.94]). 30 No study, however, has examined how these measures may be implemented in management strategies.
Circulating Biomarkers
A wide range of blood-based biomarkers have been associated with arrhythmia recurrence after AF ablation (Supplementary Material 
Fibrosis and Extracellular Matrix Remodelling
Atrial fibrosis is a common endpoint of a variety of AF-promoting conditions, and AF itself induces remodelling and fibrosis. 38 Fibrosis promotes AF through disruption of intermyocyte coupling, local conduction disturbances, arrhythmogenic fibroblast-myocyte interactions and heterogeneities in conduction properties and repolarisation. 39 Circulating biomarkers of fibrosis associated with post-ablation AF recurrence are summarised in Supplementary Material Table 4 .
Genetic Predictors of AF Recurrence
Genome-wide association studies and candidate gene studies have identified numerous polymorphisms associated with the risk of newonset AF. 40, 41 A subset of these have been associated with AF recurrence after ablation, as well as with extra-PV triggers, pre-existent LA scars and LA diameter. 42, 43 In addition, genetic polymorphisms involved in inflammation, fibrosis and myocardial injury have been associated with post-ablation AF recurrence. [44] [45] [46] While these data provide valuable insight into the underlying mechanisms, the modest predictive accuracy of genetic predictors has not translated into clinical implementation.
Electrocardiographic and Electrophysiological Parameters
Surface ECG and electrophysiology study parameters provide key information about the integrity and electrophysiological properties of the myocardium. Supplementary Material Table 5 lists examples of electrical predictors of AF recurrence after ablation.
Electrical Markers of Atrial Cardiomyopathy and Remodelling
Interatrial block (IAB), defined as a P wave ≥120 ms on any ECG lead, is a frequent condition generally resulting from impaired conduction within Bachmann's region or adjacent atrial myocardium. 47 Table 5 ). Regardless of the specific measure, greater AF disorganisation/complexity (for example short AF cycle length, high dominant frequency, low f wave amplitude, low spectral organisation, high entropy) is predictive of worse rhythm outcomes, likely because these parameters are related to a shorter atrial refractory period, more numerous simultaneous wavelets and atrial fibrosis. 55 Moreover, AF seems to progressively organise within the 60-120 seconds preceding spontaneous termination, as shown by Alcaraz and Rieta's sample entropy, a non-linear measure of signal regularity. 56, 57 Importantly, organisation parameters show a progressive decline in AF complexity in response to successful ablation compared with unsuccessful ablation, as shown with AF cycle length, dominant frequency (DF) and spectral organisation index. [58] [59] [60] AF electrical complexity parameters show promise to refine patient selection and have been proposed to monitor the effect of ablation during stepwise procedures. 59 The impact on long-term outcomes remains to be determined.
The extent to which AF complexity parameters could help identify ablation targets remains controversial. Atienza et al. performed biatrial DF mapping using 3D electroanatomic mapping in 50 consecutive patients (64% paroxysmal AF) and ablated sites of local maximum DF (DFmax), followed by PVI and post-ablation DF assessment. 61 
Functional Endpoints for AF Ablation

Non-inducibility
By analogy with other tachyarrhythmias in which persistent inducibility at procedure end is indicative of a poor arrhythmia prognosis, AF noninducibility has been investigated as a tailored procedural endpoint for AF ablation. AF inducibility has been tested using two different modalities with different conceptual goals: rapid atrial pacing, or burst pacing, assesses sustainability, i.e. the capacity of the heart to maintain AF over time, thereby assessing the extent of AF-maintaining substrate, while isoproterenol infusion assesses the propensity of the heart to initiate AF, thereby identifying AF-triggering foci.
Non-inducibility by Atrial Burst Pacing
A normal heart should not sustain AF for more than a limited period of time -in the order of a few seconds for experimental models such as goats. 63 In human studies, the majority of patients with healthy hearts did not sustain induced AF for ≥5 minutes, although the proportions varied with the induction protocol. 64 Therefore, sustained induced AF is considered indicative of AF-maintaining substrate and, eventually, a marker of structural and electrophysiological remodelling.
AF inducibility at procedure end (most commonly PVI alone) has been reported to predict AF recurrence in numerous studies. 65, 66 In addition,
we recently demonstrated that a progression of AF inducibility from de novo AF ablation to repeat procedures was strongly associated with worse arrhythmia outcomes. 67 Moreover, inducibility was shown to decline with additional ablation beyond PVI. 58 As a result, inducibility has been used as a procedure endpoint in stepwise AF ablation protocols and recent evidence suggests that AF non-inducibility may be a better indicator of outcome than AF termination. 58, 68, 69 Consistent with a relationship to AF substrate, AF inducibility has also been shown to be a strong predictor of new-onset AF in patients undergoing typical atrial flutter ablation. 70 Finally, an ablation strategy aimed at achieving AF non-inducibility by electrogram-guided ablation lines has been found to improve arrhythmia outcomes in one RCT. 71 However, the prognostic value of AF inducibility has not been reproduced consistently across studies. 65, 72 Moreover, the particular substrate modification strategy used to achieve AF non-inducibility is likely a critical determinant of outcome, yet none of the adjunctive ablation strategies investigated to date have an established benefit beyond PVI.
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The value of AF inducibility as a procedure endpoint is likely to be dependent on the induction protocol and on the cut-off duration used to define sustained AF; more data are needed to determine the limits of AF inducibility and sustainability in health and disease and how it relates to clinical outcomes after ablation.
Non-inducibility by Isoproterenol Infusion
High-dose isoproterenol infusion (typically up to 20-30 µg/min for ≥10 minutes) can be used to provoke non-PV triggers, allowing them to be located for ablation. While PV triggers are present in >90% of AF patients, including persistent and long-standing persistent AF, 74 non-PV AF-triggering foci have also been reported in 11-32% of patients undergoing AF ablation. [74] [75] [76] [77] The most common locations include the superior vena cava, the CS, the ligament of Marshall, the posterior LA wall, the mitral valve annulus, the LA appendage and the crista terminalis/eustachian ridge. [74] [75] [76] 78 The presence of non-PV triggers at de novo AF ablation has been consistently reported as a predictor of AF recurrence. 75, [79] [80] [81] [82] [83] Crawford et al. reported AF inducibility by isoproterenol infusion to predict AF recurrence at 12 months with 33% sensitivity, 97% specificity and 83% accuracy. 84 Recently, Hojo et al. assessed non-PV triggers in 216 patients (80% paroxysmal AF) who underwent de novo PVI followed by a second procedure at 6 months. 85 The authors found a strong association between development of non-PV triggers and AF recurrence: 24.1% of patients with newly developed non-PV triggers had AF recurrence versus 7.4% of patients without newly developed non-PV triggers. Other observational studies have reported improved long-term outcomes after de novo AF ablation when non-PV triggers were identified by isoproterenol infusion and ablated. 79 Of note, heterogeneous definitions of 'significant' non-PV triggers and ablation strategies have been used leading to heterogeneous results. 86 Despite promising results, the lack of RCTs warrants caution. As a result, isoproterenol infusion and non-PV triggers ablation remains a Class IIB recommendation in the 2017 international expert consensus statement on catheter and surgical ablation of AF.
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Termination
The rationale for using termination as an endpoint of CA is to demonstrate efficient modification/elimination of the atrial substrate necessary to sustain AF. By analogy with other tachyarrhythmias, termination of a long-lasting arrhythmia during radiofrequency delivery can be attributed to the functional elimination of a critical driving mechanism. Of note, this endpoint has limited value for paroxysmal AF ablation since spontaneous termination may be fortuitous.
AF termination during stepwise ablation of persistent AF has been reported to predict AF recurrence in several studies. 6, 21, [87] [88] [89] The mode of AF termination (directly to sinus rhythm versus via transformation into atrial tachycardia [AT]) was not predictive of recurrence in the majority of studies, but AF termination at index ablation seems associated with a greater proportion of recurrences in the form of AT relative to AF (with a lower total number of arrhythmia recurrences compared to patients without termination). 65, 87 This could be explained by differences in the lesion set between patients with termination and without termination, since studies investigating termination used stepwise ablation aimed at AF termination.
It should be noted, that other studies have shown conflicting results. 65 The question was addressed in a substudy of the Substrate and Trigger
Ablation trigger elimination may allow for more parsimonious ablation than the sometimes-extensive lesion set required to achieve acute termination. As suggested above, the role of termination per se has hardly been studied,
given that the ablation strategies were guided by termination itself. In conclusion, AF termination seems to indicate a more favourable prognosis but alternatively may simply select a subgroup with a limited and ablationsensitive set of driver mechanisms. 
Summary
Clinical Perspective
• Clinical AF phenotype is an established stratification criterion to determine the indication to catheter ablation, but more individualised and objective selection is needed to improve outcomes.
• A number of predictors of AF ablation success based on clinical, electrophysiological, imaging and biological data may allow the identification of patients with very low probability of ablation success with current ablation strategies in these patients.
• In selected patients, such as those with HF, sinus rhythm restoration by early intervention may prevent disease progression and improve long-term outcomes.
• Individualised procedure endpoints, including AF termination and non-inducibility, have shown promise to achieve improved arrhythmia outcomes via patient-specific lesion sets, but the lack of an established ablation strategy limits clinical inference.
• Substrate-based ablation strategies based on delayedenhancement MRI or selected electrophysiological surrogates are promising areas of progress.
